YP05002 / Fosun Pharma - LARVOL DELTA

Pfizer…announced it has entered into an exclusive global collaboration and license agreement with YaoPharma…for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight management (Businesswire) - "Under the terms of the agreement, YaoPharma will complete an ongoing YP05002 Phase 1 clinical trial and grants Pfizer an exclusive license to further develop, manufacture and commercialize YP05002 worldwide....Pfizer plans to conduct combination studies of YP05002 with its glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist PF-07976016..."

Licensing / partnership • New trial • Obesity

YP05002, A Small Molecule GLP-1RA With Superior Weight Loss and Potential for Once Weekly Dosing (OBESITY WEEK 2025) - "We have discovered YP05002, a novel oral small molecule GLP-1RA with exceptional properties in preclinical models. The goal of this molecular design is to achieve superior weight loss effect, relatively easier drug administration, and potentially enhance tolerability."

Alzheimer's Disease • CNS Disorders • Diabetes • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Type 2 Diabetes Mellitus

A Study of YP05002 in Healthy Participants (clinicaltrials.gov) - P1 | N=76 | Not yet recruiting | Sponsor: Yaopharma Co., Ltd.

New P1 trial

A Study of YP05002 in Healthy Participants (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: Yaopharma Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open